The warning reads: The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of OZEMPIC
Zapata, L
Omada Health offers support and guidance between visits for individuals using GLP-1s, including evidence-based exercise programs focused on maintaining and building muscle mass before, during, and after GLP-1 use to support metabolic function, mitigate weight regain, and help individuals achieve and maintain better health
Observational studies of patients on GLP-1 medications post-cholecystectomy show that nausea, constipation, and diarrhea occur at similar or sometimes slightly lower rates compared to gallbladder-intact cohorts
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical Biology and Mechanisms of Action
What is the potential impact of new government plans to provide Medicare coverage for GLP-1s and deals with pharmaceutical companies to provide these medications at lower costs